These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 15781427)

  • 1. Influence of tumours on normal cells and optimal chemotherapy regimens: the case of several drugs and toxicity constraints.
    Matveev AS; Savkin AV
    Math Med Biol; 2005 Jun; 22(2):143-62. PubMed ID: 15781427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal chemotherapy regimens: influence of tumours on normal cells and several toxicity constraints.
    Matveev AS; Savkin AV
    IMA J Math Appl Med Biol; 2001 Mar; 18(1):25-40. PubMed ID: 11339336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The optimal scheduling of two drugs with simple resistance for a problem in cancer chemotherapy.
    Murray JM
    IMA J Math Appl Med Biol; 1997 Dec; 14(4):283-303. PubMed ID: 9415996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The optimal dose of CAF regimen in adjuvant chemotherapy for breast cancer patients at stage IIB.
    Khaloozadeh H; Yazdanbakhsh P; Homaei-shandiz F
    Math Biosci; 2008 Jun; 213(2):151-8. PubMed ID: 18533195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing drug regimens in cancer chemotherapy by an efficacy-toxicity mathematical model.
    Iliadis A; Barbolosi D
    Comput Biomed Res; 2000 Jun; 33(3):211-26. PubMed ID: 10860586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiangiogenic therapy: a universal chemosensitization strategy for cancer?
    Kerbel RS
    Science; 2006 May; 312(5777):1171-5. PubMed ID: 16728631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy burden, drug resistance, and optimal treatment regimen for cancer chemotherapy.
    Boldrini JL; Costa MI
    IMA J Math Appl Med Biol; 2000 Mar; 17(1):33-51. PubMed ID: 10757031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Dosage regimen optimization in cancer chemotherapy using a mathematical model].
    Barbolosi D; Freyer G; Ciccolini J; Iliadis A
    Bull Cancer; 2003 Feb; 90(2):167-75. PubMed ID: 12660135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Norton-Simon hypothesis: designing more effective and less toxic chemotherapeutic regimens.
    Simon R; Norton L
    Nat Clin Pract Oncol; 2006 Aug; 3(8):406-7. PubMed ID: 16894366
    [No Abstract]   [Full Text] [Related]  

  • 10. Modelling chemotherapy resistance in palliation and failed cure.
    Monro HC; Gaffney EA
    J Theor Biol; 2009 Mar; 257(2):292-302. PubMed ID: 19135065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy.
    Munoz R; Man S; Shaked Y; Lee CR; Wong J; Francia G; Kerbel RS
    Cancer Res; 2006 Apr; 66(7):3386-91. PubMed ID: 16585158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic therapy for metastatic colorectal cancer: current options, current evidence.
    Kelly H; Goldberg RM
    J Clin Oncol; 2005 Jul; 23(20):4553-60. PubMed ID: 16002847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contrasting effects of extended low dose versus standard dose shorter course UFT chemotherapy on microscopic versus macroscopic established tumors: implications for optimal postoperative adjuvant chemotherapy.
    Uchida J; Okabe H; Nakano K; Fujioka A; Saito H; Sugimoto Y; Oka T; Fukushima M
    Oncol Rep; 2007 Aug; 18(2):313-9. PubMed ID: 17611650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of good risk germ-cell tumours.
    Troost MM; Sternberg CN; de Wit R
    BJU Int; 2009 Nov; 104(9 Pt B):1387-91. PubMed ID: 19840018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A qualitative approach to cell growth modeling and simulation for cancer chemotherapy.
    Gaglio S; Giacomini M; Nicolini C; Ruggiero C
    IEEE Trans Biomed Eng; 1991 Apr; 38(4):386-9. PubMed ID: 1855803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose combination chemotherapy: why, how, and when.
    Israël L
    Mt Sinai J Med; 1985 Jun; 52(6):447-51. PubMed ID: 3875024
    [No Abstract]   [Full Text] [Related]  

  • 17. Mathematical modelling for the assessment of the effect of drug application delays in metronomic chemotherapy of cancer due to physiological constraints.
    Mukherjee A; Majumder D
    Biosystems; 2008 Jan; 91(1):108-16. PubMed ID: 17889991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.
    Bigioni M; Benzo A; Irrissuto C; Lopez G; Curatella B; Maggi CA; Manzini S; Crea A; Caroli S; Cubadda F; Binaschi M
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):621-9. PubMed ID: 18038274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy.
    Shayne M; Culakova E; Poniewierski MS; Wolff D; Dale DC; Crawford J; Lyman GH
    Cancer; 2007 Oct; 110(7):1611-20. PubMed ID: 17705197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy.
    Munoz R; Shaked Y; Bertolini F; Emmenegger U; Man S; Kerbel RS
    Breast; 2005 Dec; 14(6):466-79. PubMed ID: 16199161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.